Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Galectin Therapeutics Inc. (GALT) had Return on Equity of 4.28% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-5.56M |
|
-- |
|
-- |
|
$3.37M |
|
$-3.37M |
|
$-2.13M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-5.50M |
|
$-3.37M |
|
$-3.32M |
|
63.90M |
|
63.90M |
|
$-0.08 |
|
$-0.08 |
|
| Balance Sheet Financials | |
$19.44M |
|
-- |
|
$0.10M |
|
$19.53M |
|
$8.03M |
|
$133.74M |
|
$137.70M |
|
$145.73M |
|
$-128.41M |
|
$-126.19M |
|
$-126.19M |
|
65.20M |
|
| Cash Flow Statement Financials | |
$-23.88M |
|
-- |
|
$26.48M |
|
$15.12M |
|
$17.72M |
|
$2.60M |
|
$1.66M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.42 |
|
-- |
|
-- |
|
17.74 |
|
-1.06 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-23.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
4.28% |
4.36% |
|
-28.16% |
|
-72.94% |
|
$-1.94 |
|
$-0.37 |
|
$-0.37 |
|